Pragmatic Clinical Trial
Pragmatic Randomized Controlled Trial (Pragmatic RCT) · Also known as: pragmatic trial, real-world trial, effectiveness trial, PRECIS-2
A pragmatic trial is designed to evaluate the real-world effectiveness of an intervention in typical clinical settings with diverse, representative patients, minimal exclusion criteria, and clinically relevant outcomes. Developed by Thorpe and colleagues (2009) and formalized via the PRECIS-2 framework (2015), pragmatic trials bridge the gap between explanatory efficacy trials (conducted in controlled research settings) and implementation science, answering the question 'Does this work in actual clinical practice?' rather than 'Can this work under ideal conditions?'
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Use pragmatic designs for: (1) testing interventions ready for clinical practice (not early-stage drugs or investigational devices), (2) comparing alternative treatments both reasonable in clinical practice (e.g., surgical approach A vs B; drug X vs Y), (3) evaluating implementation strategies, quality improvement initiatives, or complex interventions (multiple components, user adaptation), (4) answering questions relevant to clinicians and health systems ('Should we adopt this intervention?'), (5) assessing real-world effectiveness in diverse populations, (6) measuring clinically meaningful outcomes (mortality, symptom resolution, cost, patient satisfaction), (7) integrating research into routine practice (minimal disruption to normal care flow).
Strengths & limitations
- High generalizability: broad inclusion criteria and real-world setting mean results apply to typical patients in clinical practice.
- Real-world evidence: addresses implementation barriers, adherence, patient preferences, and costs—critical for practice change.
- Efficiency: integrates into routine clinical care, reducing research overhead and cost.
- Clinically meaningful outcomes: focuses on outcomes that matter to patients (mortality, function, quality of life) not just biomarkers.
- Heterogeneity visibility: diverse participants reveal subgroups where intervention is more or less effective, informing personalized practice.
- Reduced internal validity: pragmatic design prioritizes external validity; lack of tight control increases noise and may require larger sample sizes for same power.
- Loss to follow-up: real-world participants are harder to retain; high attrition threatens validity if systematic.
- Implementation variability: intervention delivered variably across sites/clinicians; difficult to assess fidelity or identify which components drive effect.
- Confounding: observational aspects (participants self-select into arms, clinician behavior varies) introduce confounding despite randomization.
- Interpretability: 'noisy' results with wide confidence intervals are common, making clinical decisions harder.
Frequently asked
What is the difference between a pragmatic trial and an explanatory trial?
Explanatory trials test 'Can this intervention work under ideal conditions?' They use strict inclusion criteria, intensive monitoring, trained research staff, and standardized protocols. They optimize efficacy (effect in a homogeneous, controlled population). Pragmatic trials test 'Does this intervention work in real practice for diverse patients?' They use broad inclusion, minimal exclusions, real-world delivery, and clinically relevant outcomes. They measure effectiveness (real-world impact). Both use randomization (gold standard). The distinction is on a continuum (PRECIS-2 scores), not binary. Many modern trials are hybrid, with some pragmatic and some explanatory domains.
Why might a pragmatic trial show smaller effect sizes than an explanatory trial of the same intervention?
Pragmatic trials recruit diverse participants with comorbidities, variable adherence, and real-world support—heterogeneous and often less amenable to treatment. Explanatory trials use selected, homogeneous participants with high adherence and intensive support—more responsive to treatment. Additionally, pragmatic trials often employ intent-to-treat analysis (accounts for non-adherence), while explanatory trials may use per-protocol analysis (excludes non-adherent). Smaller pragmatic effects are real and clinically relevant: they reflect true-world impact. A small effect in diverse, real patients is often more valuable than a large effect in selected research subjects.
How do I use PRECIS-2 to design a pragmatic trial?
PRECIS-2 has 9 domains, each scored 1–5 (1=explanatory, 5=pragmatic): (1) Eligibility: score 5 if broad inclusion, minimal exclusions. (2) Recruitment: score 5 if through routine care channels. (3) Setting: score 5 if primary care, community. (4) Delivery: score 5 if routine delivery, flexible to clinician/patient preference. (5) Flexibility: score 5 if adaptation to individual needs. (6) Adherence: score 5 if standard support only. (7) Primary outcome: score 5 if clinically relevant (mortality, hospitalization, QoL). (8) Primary analysis: score 5 if intent-to-treat in entire enrolled cohort. (9) Follow-up: score 5 if routine healthcare follow-up. Score each domain based on design choices. Ideally most domains score 4–5 for a pragmatic trial. Visualize on the PRECIS-2 wheel (spider diagram).
Should I use intent-to-treat (ITT) or per-protocol (PP) analysis in a pragmatic trial?
Intent-to-treat (ITT) is strongly preferred for pragmatic trials. ITT analyzes all randomized participants in their assigned groups regardless of adherence or protocol violations, reflecting real-world outcomes (some people don't take medications, some do). ITT is conservative, unbiased, and aligns with pragmatic philosophy. Per-protocol (analyzing only those who adhered) removes the real-world variability that pragmatic trials aim to capture; it inflates effect sizes and introduces selection bias. Report ITT as primary analysis. You may report per-protocol sensitivity analysis for context, but ITT is the pragmatic standard.
Sources
- Thorpe, K. E., Zwarenstein, M., Oxman, A. D., Treweek, S., Furberg, C. D., Altman, D. G., ... & Tugwell, P. (2009). A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ, 180(10), E47–E57. DOI: 10.1503/cmaj.090523 ↗
- Loudon, K., Treweek, S., Sullivan, F., Donnan, P., Thorpe, K. E., & Zwarenstein, M. (2015). The PRECIS-2 tool: designing trials that are fit for purpose. BMJ, 350, h2147. DOI: 10.1136/bmj.h2147 ↗
- Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., ... & Moher, D. (2018). Reducing waste from incomplete or unusable reports of biomedical research. The Lancet, 383(9913), 267–276. DOI: 10.1016/S0140-6736(13)62228-X ↗
How to cite this page
ScholarGate. (2026, June 4). Pragmatic Randomized Controlled Trial (Pragmatic RCT). ScholarGate. https://scholargate.app/en/clinical-research/pragmatic-clinical-trial
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Adaptive Trial DesignClinical Research↔ compare
- Cluster Randomized TrialClinical Research↔ compare
- Randomized Controlled TrialExperimental design↔ compare
- Real-World Evidence StudiesClinical Research↔ compare